Michael Hageman

School of Pharmacy - Pharmaceutical Chemistry
Valentino J. Stella Distinguished Professor
Primary office:
Simons 274
University of Kansas
2095 Constant Ave.
Lawrence, Kansas 66047


Professor Hageman earned his B.S. in Pharmacy and Ph.D. in Pharmaceutical Chemistry from the University of Kansas. His research experiences have included industrial positions in R&D at Pharmacia, Pfizer and Bristol-Myers Squibb. See more detail below.

Summary of Scientific Experiences
Prior to joining the Department of Pharmaceutical Chemistry at The University of Kansas as a Distinguished Professor in 2017, I spent 30+ years working in the Pharmaceutical Industry. I have extensive experience in physicochemical characterization and preclinical assessment of new chemical entities (NCE), including proteins, peptides, oligonucleotides, protein drug conjugates, prodrugs, and other small molecule based therapeutics. I have been directly involved in the Discovery process with chemical lead selection, chemical lead optimization, and drug candidate selection for transition into clinical development. Those preclinical experiences include drug delivery research for both parenteral and oral dosage form design, with particular emphasis on designing specialized formulation strategies to overcome poor drug stability and poor aqueous solubility, with the ultimate goal of enhancing developability and commercialization. I have extensive experience, and resulting patents, on the generation of solublilzed dosage forms for administration, parenteral and oral, of both immediate release and controlled release dosage forms. Similarly, critical experience in factors which influence processing technologies, such as lyophilization and spray drying for both biologics and small molecule NCE, provides a window to later phase manufacturing challenges. In depth lab work utilizes a materials characterization approach to understand the fundamental role of both physicochemical and physicomechanical properties in both the chemical and physical stability within these amorphous systems, which dictate the resulting bioperformance of these systems. I have expertise at understanding the role of polymers and excipients in both the dissolution behaviour of these solid dispersion systems and their ability to produce and maintain supersaturated drug concentrations to enhance oral absorption. My background in industrial R&D, my experience in physical analysis, formulation screening, and developability assessment of numerous different drug modalities, will all provide me the background necessary to support the practical delivery aspects of this project in a way which has a line-of-sight to clinical evaluation and a potential product..


Ph.D., Pharmaceutical Chemistry, University of Kansas

M.S., Pharmaceutical Chemistry, University of Kansas

B.S., Pharmacy, University of Kansas

Hageman CV



1985-1987 Scientist I, Pharmacy Research, Veterinary Biologics, Upjohn Co., Kalamazoo, MI
1987-1990 Scientist II, Drug Delivery R&D, Human and Veterinary, Upjohn Co., Kalamazoo, MI
1991-1996 Senior Research Scientist III, Solubilized Formulation Design, Upjohn Co., Kalamazoo, MI
1996-1999 Senior Scientist/Group Leader, Exploratory Formulations, Pharmacia & Upjohn, Kalamazoo, MI
1999-2003 Senior Fellow/Group Leader, Global Pharmaceutical Sciences Exploratory Formulations, Pharmacia Co., Kalamazoo, MI
2002-2004 Head Global Workstream for Cross-division Re-engineering of Biological Target Selection to First in Human Process, Pharmacia Co., Kalamazoo, MI
2003-2005 Sr. Res. Fellow/Group Leader, Exploratory Formulations, Pfizer Global R&D, Kalamazoo, MI
2004-2005 Chair of Michigan Cross-Divisional Pharmaceutical Sciences Technology Group, Pfizer Global R&D, Kalamazoo & Ann Arbor, MI
2005-2013 Group Director, Discovery Pharmaceutics, Bristol-Myers Squibb, Princeton, NJ
2007-2010 Pharmaceutical Candidate Optimization Site Lead, Bristol-Myers Squibb, Princeton, NJ
2012-2016 Global Matrix Team Head, Biochemical & Biophysical Characterization
Network for Biologics, Bristol-Myers Squibb, Princeton, NJ
2013-2016 Executive Director, Pharmaceutical Candidate Optimization, Discovery Pharmaceutics, Bristol-Myers Squibb, Princeton, NJ
2017-present Valentino J. Stella Distinguished Professor, Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS

Selected Publications

Representative Publications can be found here.

Editorial Activities
Editor for the Journal of Pharmaceutical Sciences
(Editorial Board Here)
Challenges and Rewards
Editors: Stella, V., Borchardt, R., Hageman, M., Oliyai, R., Maag, H., Tilley, J. (Eds.)
Optimizing the "Drug-Like" Properties of Leads in Drug Discovery
Editors: Borchardt, R., Kerns, E., Hageman, M., Thakker, D., Stevens, J. (Eds.)


One of 34 U.S. public institutions in the prestigious Association of American Universities
44 nationally ranked graduate programs.
—U.S. News & World Report
Top 50 nationwide for size of library collection.
5th nationwide for service to veterans —"Best for Vets: Colleges," Military Times
KU Today

Our research projects ranging from traditional pharmaceutics to biotechnology. 

Learn more here.